NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Cancer > First person receives drug designed to re-sensitise patients to cancer treatment

First person receives drug designed to re-sensitise patients to cancer treatment

10 August 2021 · Listed under Cancer

The first patient has been dosed using a new drug aimed at improving treatment options for melanoma and non-small cell lung cancer (NSCLC) and re-sensitising patients with checkpoint therapy-resistant tumours

The IMP-MEL clinical trial began in Oxford with its first patient being dosed with the new drug PORT-2. The Oxford-led study is investigating the tolerability and efficacy of PORT-2, a drug that was developed to target invariant natural killer T (iNKT) cells and trigger a cancer-specific B and T cell response to tumours.

The study, which is supported by the NIHR Oxford Biomedical Research Centre (BRC), is expected to enrol 100 patients in Oxford and other centres, and will evaluate PORT-2 both as a monotherapy and in combination with approved PD-1 inhibitor drug Keytruda in the treatment of melanoma and NSCLC.

An additional aspect of the PORT-2 drug is that it has the potential to re-sensitise checkpoint-resistant tumours to treatment with PD-1 antibodies. Not all patients’ tumours respond to current immune-oncology agents, with most cancer types totally insensitive to treatment.

Re-sensitising patients is one approach to make existing cancer drugs more effective and appropriate in the treatment of many patients’ cancers.

Professor Mark Middleton, Head of the University of Oxford’s Department of Oncology and the Oxford BRC’s Co-theme Lead for Cancer, said: “Checkpoint inhibitor therapies have enormous opportunity in the treatment of solid tumours, but unfortunately, many cancers develop a resistance to these therapies, leaving many patients without adequate treatment options.

“We’re constantly seeking new therapies that are capable of addressing resistance and enabling a durable response in patients with cancer. Should PORT-2 prove successful, this novel iNKT agonist therapy could potentially re-sensitise patients to checkpoint inhibitor treatment and could activate that durable immune response. It’s a very exciting new avenue for oncology research,” said Prof Middleton, who is leading the trial, which has received support from Portage Biotech.

Read more.

← Oxford Cancer launched at the University of Oxford
New multi-cancer early detection blood test study opens →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre